Pain Management & Opioids: Balancing the Risks & Benefits

Thursday, December 12, 2019
6 p.m. to 7 p.m.
Three Rivers Health
701 South Health Parkway
Three Rivers, MI 49093
Rocky River Conference Room

There is NO cost for this training. Dinner will be provided.

To register go to:
wmich.edu/hhs/academics/continuing-ed
Or e-mail:
Lisa.Brennan@wmich.edu

Tammy O. Graves, DO
Pediatric Critical Care
Bronson
Methodist Hospital

Learning objectives:
• Describe the pathophysiology of pain as it relates to the concepts of pain management.
• Accurately assess patients in pain.
• Develop a safe and effective pain treatment plan.
• Identify evidence-based non-opioid options for the treatment of pain.
• Identify the risks and benefits of opioid therapy.
• Manage ongoing opioid therapy.
• Recognize behaviors that may be associated with opioid use disorder.

WRAHEC has partnered with Interstate Postgraduate Medical Association. IPMA is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. IPMA designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation.

Designation Statement: The Interstate Postgraduate Medical Association of North America (IPMA) will provide the CMEs for this program
Faculty Disclosure: Unknown presenter reports he/she (or spouse/partner) has no relevant financial relationships, arrangement or affiliation with commercial interests or pharmaceutical companies, over the past 12 months, whose products or services may have relevance to the content of this presentation. The presenter will not discuss or refer to the use of therapeutic agents or other commercial products that are not FDA approved, including the use of products or treatments that is contrary to the labeling or unestablished medical practices.
Planner Disclosure: Planners (or spouse/partners) reported as having no financial interest, arrangement or affiliation with commercial interests or pharmaceutical companies over the past 12 months whose products may have relevance to the content of this presentation.